-
Abstract Number: PB2286
Radiological Parameters on Computed Tomography Pulmonary Angiography Correlate Poorly with Early Mortality from Acute Pulmonary Embolism
-
Abstract Number: PB1160
Raising Factor VIII’s Half-life to the Next Level
-
Abstract Number: PB1360
Randomized Study for the Treatment of Primary Immune Thrombocytopenic Purpura (pITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone versus High-dose Dexamethasone. Preliminary Results. GIMEMA Protocol ITP0207
-
Abstract Number: PB1618
Rap1a/b Isoforms Differentially Regulate Megakaryocyte Biology
-
Abstract Number: PB1064
Rapid Desensitization and Subsequent Immune Tolerance Induction in a Patient with Hypersensitivity and Inhibitor to Factor VIII
-
Abstract Number: PB0686
Rapid Latex Enhanced Immunoassay (LIA) for Heparin Induced Thrombocytopenia and False Positivity
-
Abstract Number: PB0307
Rapid Thaw Plasma Units Thaw Significantly Faster than Standard Plasma Units while Retaining Similar Coagulation Profile over 5 Days of Cold Storage
-
Abstract Number: PB0207
Rare Bleeding Disorders in North India – Study from a Tertiary Care Centre
-
Abstract Number: PB1167
Rare Bleeding Disorders in Southern Iran: Revisited and Updated Data
-
Abstract Number: PB0176
Rare Coagulation Disorders in Children – Is it Like to Buy a Pig in a Poke or Nothing Special? Experience of Saint Petersburg, Russia
-
Abstract Number: PB2059
Rates, Management and Outcome of Bleeding Complications during Edoxaban Therapy in Daily Care – Results from the Dresden NOAC Registry
-
Abstract Number: PB2050
Ratio of Inhibited Thrombin Generation Based on Dilute Prothrombin Time May Predict the Major Bleeding or Thrombotic Tendency in NVAF Patients Treated with Anti-Xa DOAC
-
Abstract Number: PB0120
Rationale and Design for the Study Apixaban versus ClopidoGRel on a Background of Aspirin in Patients Undergoing InfraPoPliteal Angioplasty for Critical Limb Ischemia – AGRIPPA Trial
-
Abstract Number: PB0910
Rationale and Study Design for a Prospective, Low-Interventional Study to Investigate whether Systematic Joint Examination Impacts Haemophilia Treatment Management Decisions in Patients with Haemophilia A in France: The A-MOVE Study
-
Abstract Number: PB2371
Real Life Experience of an Antithrombotic Stewardship Program for Thrombosis Prophylaxis during Hospitalisation in a Large Teaching Hospital
-
Abstract Number: PB0785
Real Life Experienceon 61 Acquired Haemophilia A (AHA) Patients from a Single Center
-
Abstract Number: PB0877
Real Life Use of Emicizumab in Pediatric Patients without Inhibitors
-
Abstract Number: PB0935
Real World Efficacy of Emicizumab in Haemophilia A with Inhibitors: A Report from the UK National Haemophilia Database
-
Abstract Number: PB1591
Real World Experience of Major Surgery and Delivery in Von Willebrand Disease
-
Abstract Number: PB0796
Real World Experience on Use of Susoctocog-alfa (rpFVIII) in the Treatment of a Population of Italian Elderly Patients with Acquired Haemophilia A
-
Abstract Number: PB1072
Real World Experience with Rurioctocog Alfa Pegol in Vall d´Hebron University Hospital
-
Abstract Number: PB0349
Real-life Inter-individual Variability of Pharmacokinetics – Reason for Individualization of Replacement Therapy in Haemophilia
-
Abstract Number: PB1550
Real-life Management of Digestive Endoscopies: Is There a Bleeding Risk for Patients with von Willebrand Disease?
-
Abstract Number: PB0148
Real-time in vivo Visualization of Infused FVIIa in Hemophilia A Mice Following Injury
-
Abstract Number: PB0655
Real-time Intra-site and Multi-site Correlations and Evaluation of Time Stability with the Same Frozen Plasmas Kits which Cover the Full Measuring Range for Routine Tests and Anticoagulant Monitoring Tests
-
Abstract Number: PB0340
Real-world Analysis of Hemophilia Patients in China: A Single Center’s Experience
-
Abstract Number: PB0873
Real-World Cost of Emicizumab
-
Abstract Number: PB0948
Real-World Data of First-Time and Rescue Immune Tolerance Induction with Recombinant Factor VIII Fc Fusion Protein in Patients with Hemophilia A with Inhibitors in Japan: “Fc Adolescent and Children Treatment” Study (FACTs) Part 2 Interim Analysis
-
Abstract Number: PB0879
Real-World Effectiveness Evaluation of the Recombinant Factor VIII Fc Fusion Protein in Adolescents and Children with Hemophilia A in Japan: “Fc Adolescent and Children Treatment” Study (FACTs) Part 1 Interim Analysis
-
Abstract Number: PB1051
Real-world Evidence on the Use of rIX-FP in Patients with Hemophilia B: Interim Results from Three Multinational Prospective, Non-interventional, Post-market Surveillance Studies
-
Abstract Number: PB0980
Real-World Experience of rVIII-SingleChain Treatment in a French Single Center
-
Abstract Number: PB0928
Real-World Experience with Emicizumab in Persons with Hemophilia A (HA) with or without Inhibitors
-
Abstract Number: PB0919
Real-World Outcomes before and after Switching from Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in the United States
-
Abstract Number: PB0779
Real-World Use of Recombinant B-Domain-Deleted, Porcine-Sequence Factor VIII in Patients with Acquired Hemophilia A: An Interim Analysis of the Post-Authorization Safety Study in the European Union (EU)
-
Abstract Number: PB2394
Reasons and Associated Outcomes in Delayed Anticoagulation in Venous Thromboembolism
-
Abstract Number: PB2511
Reassessment of Venous Thromboembolism Risk and Prophylaxis in Post-Delivery Period of Healthy Women
-
Abstract Number: PB2208
Recanalization of Venous Thrombosis by Robotic Assisted High Frequency Pulsed Cavitational Ultrasound Therapy: 2 Weeks Follow-up in a Swine Model
-
Abstract Number: PB1545
Recombinant Human von Willebrand Factor (rVWF) Differs in Structure and Function from Plasma Derived Concentrates
-
Abstract Number: PB1558
Recombinant von Willebrand Factor (rVWF) in Patients with von Willebrand Disease (VWD) Undergoing Elective or Emergency Surgery in Real World Setting – The Dijon University Hospital Experience from March 2019 to January 2020
-
Abstract Number: PB1224
Recommendation on the Treatment of Venous Thromboembolism in Cancer Patients at a Brazilian Public Oncological Institution: Educational Plan
-
Abstract Number: PB2328
Recovery from Acute Kidney Injury in Patients with Pulmonary Embolism: A Monocenter Study
-
Abstract Number: PB1937
Recurrence of Thrombotic Events in Antiphospholipid Syndrome Patients Receiving Prolonged Vitamin K Antagonists Therapy
-
Abstract Number: PB0397
Red Blood Cells Support Factor X Activation via Intrinsic Tenase
-
Abstract Number: PB1963
Redox Regulation of Neutrophil Mac-1 Function by Protein Disulphide Isomerase
-
Abstract Number: PB2041
Reduced Bleeding After an Intervention to Limit Excess Aspirin Use Among Patients on Chronic Warfarin
-
Abstract Number: PB1532
Reduced Cleavage of Circulating Ultra-large von Willebrand Factor by ADAMTS13 Exacerbates Microvascular Disease Following Traumatic Injury
-
Abstract Number: PB1642
Reduced GPVI Signalling in Genetic and Disease Models of Thrombocytopenia
-
Abstract Number: PB0834
Reduced Splenic T Cells Count in an Untreated Mouse Model of Severe Hemophilia A
-
Abstract Number: OC 01.4
Reduction of Intracellular Sodium Protects from Inflammation and Atherosclerotic Plaque Progression
-
Abstract Number: PB2548
Reduction of Thromboembolic Disorders in Pregnancy and Postpartum Period: Role of National Pregnancy Heart Team
-
Abstract Number: PB/CO18
Reduction of Venous Thromboembolic Events in Hospitalized Patients with Coronavirus Disease 2019 after Intensification of Thromboprophylaxis
-
Abstract Number: PB1743
Reelin Modulates Glycoprotein VI and Integrin Outside-in Signaling of Platelets
-
Abstract Number: PB2568
Reference Ranges for Hemostasis Parameters during ¨Pregnancy and Puerperium
-
Abstract Number: PB1032
Reference Ranges of HJHS Scores in Healthy Adult Males without Hemophilia
-
Abstract Number: PB0601
Reference Values of 117 Healthy Donors on the ST Genesia with the STG-BleedScreen, STG-DrugScreen and STG-ThromboScreen Reagents
-
Abstract Number: PB1442
Refractory Thrombocytopenia with TUBB1 Variants: Clinical Features and Responses to Eltrombopag Treatment
-
Abstract Number: PB1865
Relapsing or Refractory Thrombotic Microangiopathies: The Key Role of ADAMTS13 Activity and Complement Testing
-
Abstract Number: PB2239
Relation between the von Willebrand Factor and ADAMTS13 with Venous Thrombosis Risk. Results from the Retrove Project
-
Abstract Number: PB0042
Relationship between Distal Venous Thrombosis and Asymptomatic Atherosclerotic Disease
-
Abstract Number: PB1787
Relationship between HAART treatment and Markers of Coagulation among People Living with HIV/AIDS (PLWHA) in Gombe, Nigeria
-
Abstract Number: PB1333
Relationship between Platelet Function and Glycome Composition in Immune Thrombocytopenia
-
Abstract Number: PB2042
Relationship between TTR and Daily Vitamin K Intake in Patients Taking Warfarin: The Difference among VKORC1 Genotype
-
Abstract Number: PB2066
Relationship of Health Literacy and Adherence to Treatment with Oral Anticoagulants in Patients with Atrial Fibrillation in Brazil
-
Abstract Number: PB2338
Relevance of Immobility as Deep Vein Thrombosis Risk Factor for Medically Ill Patients
-
Abstract Number: PB0265
Relevance of Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 p.Thr309Lys Variant
-
Abstract Number: PB2234
Relevance of Thrombophilia Screening in Adult Renal Transplant Recipients
-
Abstract Number: PB0145
Reported Values and Methodologies for Detecting Plasma D-dimer in Rat Models: A Systematic Review and Meta-analysis
-
Abstract Number: PB1156
Rescue of the Endogenous FVIII Expression in Hemophilia A Mice Using CRISPR/Cas9 Gene Editing
-
Abstract Number: PB0882
Resolution of Target Joints (TJs) in Children with Severe Haemophilia A (HA) Treated with Turoctocog Alfa Pegol (N8-GP) Prophylaxis: Results from the Pathfinder 5 Trial
-
Abstract Number: PB1363
Response Rate and Response Duration after Discontinuation of Treatment with Thrombopoietin Receptor Agonists (TPO-RAS) in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study. Preliminary Results. GIMEMA Protocol ITP0714
-
Abstract Number: PB1349
Response to Avatrombopag (AVA) in Chronic Immune Thrombocytopenia: Alternative Efficacy Measures
-
Abstract Number: PB1571
Response to Desmopressin Acetate in Von Willebrand Disease Type 2
-
Abstract Number: PB1549
Response to Treatment for Gastro-Intestinal Bleeding in von Willebrand Disease
-
Abstract Number: PB1169
Results from a Phase 4, Real-World Study Confirm the Safety and Effectiveness of rFXIII-A2 for the Treatment of Congenital FXIII A-Subunit Deficiency
-
Abstract Number: PB2213
Results of a Dedicated Diagnostic Work-up of Patients with Post-PE Syndrome
-
Abstract Number: PB0653
Results of Anti-Xa Activities for Monitoring Therapeutic and Prophylactic Doses of Low Molecular Weight Heparin in Children
-
Abstract Number: PB2332
Retinal Vein Thrombosis and the Association with Inherited Thrombophilia, Cardiovascular Risk Factors and the Risk of Occult Cancer. a Prospective Study
-
Abstract Number: PB1237
Retrospective Analysis of Characteristics and Outcomes of 340 Pediatric ITP Patients in One Center
-
Abstract Number: PB1555
Retrospective Chart Review of Gastrointestinal Bleeding in Patients with von Willebrand Disease: Study Design and Initial Demographic Results
-
Abstract Number: PB1870
Retrospective Study of 30 TTP Patients from 2017 to 2019 in a Single Center of Suzhou, China
-
Abstract Number: PB2438
Retrospective Study of Patients with Upper Extremity Clots Presenting to Emergency Departments in Tertiary Care Hospitals in a Major Canadian City in the Last Five Years
-
Abstract Number: PB0317
Reversal of Dabigatran by Idarucizumab in Heart Transplantation Surgery: A Case Report
-
Abstract Number: PB1112
Reversal of Direct Oral Anticoagulants with Three-Factor Prothrombin Complex Concentrate: Real World Experience from a Tertiary Centre in Hong Kong
-
Abstract Number: PB0306
Reversal of Heparin Anticoagulation by Andexanet Alfa (Andexanet) in Human Plasma and Whole Blood: Differential Effect of Andexanet on Antithrombin-Dependent Anticoagulants and Direct Thrombin Inhibitors (DTIs)
-
Abstract Number: PB1069
rFIXFc at Lower Doses Can Achieve Very Significant Reduction of Annualized Bleed Rates in Children with Severe Haemophilia B
-
Abstract Number: PB1061
rFVIIIFc at Lower Doses Can Achieve Clinically Meaningful Reduction of Annualized Bleed Rates in Children with Severe Haemophilia A
-
Abstract Number: PB1277
Right Atrial Thrombosis in Children: Patient Characteristics, Outcomes, and Interrater Reliability of Echocardiographic Characterization
-
Abstract Number: PB2302
Right Ventricular to Left Ventricular Diameter Ratio Assessment with Non-ECG Gated Computed Tomography Scans and its Correlation with Right Ventricular Dysfunction in Acute Pulmonary Embolism
-
Abstract Number: PB2350
Risk Factors and Frequency of Recurrent Long-Term Venous Thromboembolism After Superficial Vein Thrombosis of The Lower Limbs
-
Abstract Number: PB2306
Risk Factors and Hemostatic Aspects of Aseptic Cerebral Venous Sinus Thrombosis
-
Abstract Number: PB2316
Risk Factors and Patterns of Lower Limb Deep Venous Thrombosis in Gombe, North-Eastern Nigeria
-
Abstract Number: PB1878
Risk Factors Associated with Severe Neurological Symptoms in Thrombotic Thrombocytopenic Purpura (TTP)
-
Abstract Number: PB2539
Risk Factors for Severe Preeclampsia in Obstetric Antiphospholipid Syndrome (OAPS) with Conventional Treatment
-
Abstract Number: PB1308
Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents with Lymphomas
-
Abstract Number: PB1307
Risk Factors for the Development of Hospital-acquired Pediatric Thromboembolism – Dealing with Potentially Causal and Confounding Risk Factors Using Direct Acyclic Graph (DAG) Analysis
-
Abstract Number: OC 12.4
Risk Factors for Venous and Arterial Thrombosis in the Neonatal Intensive Care Unit (NICU)-A Multicenter Case Control Analysis
-
Abstract Number: PB2426
Risk Factors of Hemorrhagic Complications on the Anticoagulant Therapy
-
Abstract Number: PB2312
Risk Factors of Thrombotic Complications in Thai Thalassemia Patients
-
Abstract Number: PB2107
Risk Factors of Venous Thromboembolism in Patients Undergoing Systemic Cancer Therapy: A Systematic Review and Meta-Analysis
-
Abstract Number: PB2120
Risk Factors, Mortality and Costs of Cancer-Associated Thrombosis in Hospitalised Patients
-
Abstract Number: PB1810
Risk Factors, Outcomes, and Score Models of Serious Pulmonary Infection in Non-Splenectomized Immune Thrombocytopenia Adults
-
Abstract Number: PB2127
Risk of Arterial Thromboembolism in Cancer Patients: A Population-Based Cohort Study
-
Abstract Number: PB2415
Risk of Bleeding of Concomitant Antiplatelet and Anticoagulation Therapy in Patient Treated for a Venous Thormboembolic Event
-
Abstract Number: PB2474
Risk of Intracranial Bleeding in Patients with Primary Brain Cancer Receiving Therapeutic Anticoagulation for Venous Thromboembolism: A Meta-analysis
-
Abstract Number: PB2320
Risk of Receiving a Permanent Work-Related Disability Pension After Incident Venous Thromboembolism
-
Abstract Number: PB2244
Risk of Recurrence after a First-lifetime Venous Thrombosis: Impact of Inherited Thrombophilia
-
Abstract Number: PB2105
Risk of venous Thromboembolism among Subgroups of Cancer Patients Undergoing Chemotherapy: Post-Hoc Analysis of the AVERT Trial
-
Abstract Number: PB2178
Risk of Venous Thromboembolism in the Clinical Course of Osteosarcoma
-
Abstract Number: PB2339
Risk of Venous Thrombosis in the Elderly: Lifestyle and its Joint Effect with Factor V Leiden and Prothrombin 20210A
-
Abstract Number: PB1344
Risk Stratification for Intracranial Hemorrhage in Adults with Immune Thrombocytopenia: A Retrospective Multicenter Study
-
Abstract Number: PB2101
Risks and Benefits of Antithrombotic Therapy in Polycythemia Vera: A Systematic Review
-
Abstract Number: PB2563
Rituximab before Pregnancy in Refractory Obstetrical Antiphospholipid Syndrome
-
Abstract Number: PB1860
Rituximab Prolongs the Time to Relapse in Patients with Immune Thrombotic Thrombocytopenic Purpura: Analysis of Off-Label Use in Japan
-
Abstract Number: PB0639
Rivaroxaban 20 mg Oce Daily Decreases Thrombin Generation in Patients with Venous Thromboembolism for up to 24 Hours
-
Abstract Number: PB2391
Rivaroxaban for Extended Thromboprophylaxis in Acutely Ill Medical Patients 75 Years of Age or Older
-
Abstract Number: PB0612
Rivaroxaban Plasma Concentration Values and Risk Factors for Adverse Events in Patients Experiencing Bleeding: Results from a Prospective Study
-
Abstract Number: PB2393
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the Mariner Trial
-
Abstract Number: PB0167
Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1
-
Abstract Number: PB2420
Rivaroxaban versus Warfarin for Treatment and Prevention of Recurrent Venous Thromboembolism in Obese Patients
-
Abstract Number: PB0477
RMean Platelet Volume to Lymphocyte Ratio and VTE Recurrence
-
Abstract Number: PB2185
Role of ADAMTS13, VWF and FVIII in Deep Vein Thrombosis
-
Abstract Number: PB1895
Role of Anti Phosphatidylserine/Prothrombin Antibodies on Thrombin Generation and Protein C Resistance in Carriers of Antiphospholipid Antibodies
-
Abstract Number: PB1323
Role of Bone Marrow-Derived Mesenchymal Stem Cell Defects in CD8+ CD28- Suppressor T-Lymphocyte Induction in Patients with Immune Thrombocytopenia and Associated Mechanisms
-
Abstract Number: PB0383
Role of Endothelial Protein C Receptor Gene Polymorphisms (4678G>C and 6936A>G) in Young Indian DVT Patients
-
Abstract Number: PB1821
Role of Formyl Peptide Receptor 2 (FPR2/ALX) and its Anti-Inflammatory Ligand, Lipoxin A4 Analogue (BML-111) in the Modulation of Platelet Function
-
Abstract Number: PB1742
Role of HIF-2α in Promoting Thrombogenicity through PAI-1 Synthesis & EV-Releae during Adaptive Signalling in Human Platelets
-
Abstract Number: PB0188
Role of Kunitz Domain 3 of Tissue Factor Pathway Inhibitor in Zebrafish
-
Abstract Number: PB1468
Role of Multidrug Resistance Protein 4 on Both Platelet Nitric Oxide Resistance and ADP Induced Platelet Aggregation
-
Abstract Number: PB1617
Role of Platelet Production/Destruction Imbalance on the Interindividual Variability in Aspirin Response in Diabetic and Non-diabetic Patients
-
Abstract Number: PB1825
Role of Platelets in Processes of Myocardial Healing After Myocardial Ischemia and Reperfusion in Mice
-
Abstract Number: PB1737
Role of Receptor for Advanced Glycation End-products (RAGE) in Human Platelets
-
Abstract Number: PB2411
Role of Residual Pulmonary Vascular Obstruction on the Risk of Long-Term Recurrence of Venous Thromboembolism After Pulmonary Embolism: A Cohort Study
-
Abstract Number: PB1757
Role of RXRbeta in Platelet Function and Arterial Thrombosis
-
Abstract Number: PB0353
Role of Serpine2 (PN-1) in Diabetic Nephropathy
-
Abstract Number: PB2575
Role of Thrombin Generation Potential (TGP) in Cesarean Sections and Vaginal Deliveries Puerperium to Guide Thromboprophylaxis. Preliminary Results
-
Abstract Number: PB1960
Role of Thrombopoietin in Rescuing Vascular Niche of ITP Patients
-
Abstract Number: PB1338
Romiplostim Treatment in Patients with Refractory Inmune Thrombocytopenia Purpura: Experience in a Single Center
-
Abstract Number: PB0509
Rotational Thromboelastometry – A Point of Care Tool to Assess Bleeding Risks in Hemophilia A and B
-
Abstract Number: PB2537
Rotational Thromboelastometry (ROTEM) in Obstetric Population
-
Abstract Number: PB0281
ROTEM Parameters As Bleeding Predictors In Pediatric Cardiac Surgery With Cardiopulmonary Bypass
-
Abstract Number: PB0315
Routine Coagulation Assays for the Detection of Residual NOAC Levels in Patients Undergoing Elective Invasive Procedures
-
Abstract Number: PB0792
Rutin and Rutin Succinate Improve Murine Survival in an Experimental Model of Acute Hemostatic Disturbances
ISTH 2020 Congress
July 12-14, 2020. Virtual Congress.